Article Text

PDF

183 Novel glycomimetics inhibit gly-ldl induced smooth muscle cell calcification via creb
  1. Gary P Sidgwick,
  2. Ria Weston,
  3. Alan M Jones,
  4. Fiona L Wilkinson,
  5. Yvonne Alexander
  1. Manchester Metropolitan University

Abstract

Advanced glycated end-products (AGEs) are known drivers of cardiovascular complications such as vascular calcification, which is currently untreatable, and are increased in diabetic subjects in part due to oxidative stress and poor glycaemic control. Our previous studies using smooth muscle cells (SMCs) isolated from patients with peripheral arterial disease (PAD) have implicated a number of signalling pathways involved in their osteogenic differentiation in vitro, including OPG/RANK. We have also shown that alterations in the cell surface glycocalyx regulates cell function, suggesting that non-sugar glycosaminoglycan mimics can potentially modulate cell phenotypes.

We aim to investigate how modified LDL and PAD serum affects the progression of calcification of SMCs in vitro and whether this pathology can be prevented by novel glycosaminoglycan mimics, using qPCR, ELISA, Alkaline phosphatase (ALP) activity, and Western blotting.

Gly-LDL (10 µg/ml) increased an early marker of calcification (ALP activity) at 4 days and enhanced calcification at 21 days, compared to controls (p<0.05) as shown by alizarin red staining. PAD serum accelerated calcification, which was apparent after 10 days (p<0.05). The glycomimetics significantly inhibited both gly-LDL and PAD serum-induced mineralisation, and reduced gly-LDL induced ALP activity at day 4 (p<0.05). In the gly-LDL-treated SMCs, secreted levels of osteocalcin (OCN), a promoter of osteogenic differentiation, were reduced when treated with the glycomimetics, whereas osteopontin (OPN) and osteoprotegerin (OPG), inhibitors of calcification, were increased compared to gly-LDL alone. A similar trend was observed in PAD serum-treated SMCs, with glycomimetics reducing OCN and increasing OPN secretion. A phospho-kinase array analysis of gly-LDL-treated SMCs was performed to identify underlying mechanism of action. Gly-LDL increased phosphorylation of cyclic AMP response element-binding protein (CREB), TOR, and the SRC proteins LYN, YES and CHK-2 compared with untreated control, which was attenuated with the addition of the glycomimetics. A number of upstream activators of CREB were targeted using known pharmacological inhibitors in SMCs treated with gly-LDL. The MEK inhibitor U0126 accelerated calcification, increasing both ALP activity and expression of receptor for AGEs (RAGE), a key receptor implicated in vascular calcification, compared to gly-LDL alone, suggesting that MEK may be a mediator of mineralisation process via phosphorylation of CREB.

Glycomimetics have potential as an anti-calcification strategy, inhibiting mineralisation in SMCs induced by both gly-LDL and patient serum in vitro. The protective effect of glycomimetics against calcification may occur via regulation of CREB phosphorylation and subsequent modulation of downstream osteogenic markers, including upregulation of OPN and OPG and reduction of OCN, leading to the development of therapeutics to treat vascular calcification.

  • Vascular Calcification
  • Advanced Glycated Endproducts
  • Novel Therapeutics

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.